Carcinoma, Renal Cell Clinical Trial
— RENALVax-2Official title:
Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC: a Phase II Trial (RENALVax-2)
Verified date | November 2018 |
Source | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Single center, open-label Proof of Principle phase II trial to assess objective response
(ORR).
Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of
5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and
the third cycle of vaccine+IL-2. The first day of administration of vaccine is day +1 and of
IL-2 is day +2.
Treatment vaccine plus IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV infusion for 72
hours) will be administered every 3 weeks up to 6 cycles.
Total duration of the trial: 36 months
- Enrolment period: 24 months
- Treatment: maximum of 6 cycles (5 months) per patient
- Follow-up every three months until patient died (follow-up until PD and only survival
contacts and subsequent therapy for metastatic disease after PD).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2019 |
Est. primary completion date | March 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: 1. Signed Written Informed Consent: patients must be willing and able to give written informed consent, that have to be given before starting of screening procedure. 2. Availability of autologous tumor tissue fulfilling acceptance criteria prescribed by the "Product Specification File". 3. Patients must have histologically or cytologically confirmed RCC (all histology types except for urothelial cancer); 4. Patients must have stage IV disease in progression after at least 1 TKI and/or antiangiogenetic and/or mTOR inhibitors therapy (patients must have finished prior treatments at least 4 weeks before the first IL2 dose) 5. Patients must have at least one measurable lesion, according to the irRC response criteria (see section 8 ), after asportation of tumor tissue for vaccine preparation. The tumor lesions that will be irradiated are excluded for response evaluation. 6. Life expectancy of greater than 3 months. 7. ECOG performance status 0-1 8. Patients must have organ and marrow function as defined below: - leukocytes >4000/µL - absolute neutrophil count >1,500/µL - platelets >100,000/µL - total bilirubin within normal institutional limits - AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal - creatinine < 1.5 mg/dl - haemoglobin >8.0 gm/dl - hematocrit <30% 9. ECG and echocardiogram within normal institutional limits 10. Pulmonary function tests within normal institutional limits (to be performed only in patients with lung metastases or history of impaired lung function) 11. No contraindication for the use of vasopressor agents 12. Negative screening tests for HIV, HBV HCV and syphilis not older than 30 days before performing any of the GMP-regulated activities required (leukapheresis, collection of tumor biopsies to be used for tumor homogenate preparation); 13. Men and women aged > 18 years. 14. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up 8 weeks after the study, in order to minimize the risk of pregnancy; 15. Patients must have normal organ and marrow function according to clinical practice. Exclusion Criteria: 1. Patients who have positive tests to HCV, HBV, HIV, or syphilis (specific blood testing must be performed within 30 days before any GMP-regulated activity (leukapheresis and collection of tumor biopsies to be used for tumor homogenate preparation). 2. Patients who did not have prior lines of systemic therapy for advanced disease. 3. Participation in another clinical trial with any investigational agents within 30 days prior to study screening. 4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements (on physician's judgment). 5. Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 3 years (except for previously treated basal cell carcinoma and in situ carcinoma of the uterine cervix); 6. Patients who have had chemotherapy or radiotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. 7. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. 8. History of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2 or other agents used in the study. 9. Any autoimmune disease which could be exacerbated by IL-2 10. A medical illness requiring chronic treatments with corticosteroids or other immunosuppressive agents 11. A history of significant cardiovascular disease, including myocardial infarction, congestive heart failure, primary cardiac arrhythmias, angina pectoris or cerebrovascular accident 12. HIV-positivity, whether or not symptomatic 13. Any contraindication to undergo leukapheresis as evaluated by transfusionist (e.g. severe anemia, piastrinopenia, oral anticoagulant therapy) or to undergo surgery. |
Country | Name | City | State |
---|---|---|---|
Italy | UO Immunoterapia e Laboratorio TCS, IRCCS IRST | Meldola (FC) | FC |
Lead Sponsor | Collaborator |
---|---|
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate (ORR) by Immune related Response Criteria( irRC) | The analysis will be performed on an intention to treat population, i.e. all patients having received at least 2 cycles of therapy. | up to 24 months | |
Secondary | Overall survival (OS) | measured from the date of registration until the date of death from any cause or the last date the patient was known to be alive and will be estimated with Kaplan-Meier method and the log rank test | up to 24 months | |
Secondary | Duration of response | time calculated from documentation of tumor response to disease progression | up to 24 months | |
Secondary | Progression free survival | measured from registration until disease progression or death | up to 24 months | |
Secondary | Immunologic efficacy | Immunologic efficacy will be measured by best DTH score (reactivity to homogenate or KLH) obtained after at least 4 vaccine doses, alone or combined with IFN-g ELISPOT analysis of tumor antigen-specific circulating effectors obtained after a minimum of 4 vaccine doses, both compared with prevaccine samples | up to 24 months | |
Secondary | Adverse events evaluation | Number of patients with treatment related Adverse events (AE) will be evaluated by CTCAE v 4.03 criteria The percentage of patients reporting an AE up to 30 days after HD-IL-2 treatment will be tabulated with 95% confidence intervals, by type of AE. The overall rate of grade 3-4 related AE will be computed | up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02248389 -
Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses
|
Phase 1 | |
Completed |
NCT03900364 -
a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A | |
Completed |
NCT00158782 -
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
|
Phase 1 | |
Completed |
NCT03109015 -
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
|
Phase 2 | |
Completed |
NCT00363194 -
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
|
Phase 1 | |
Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
Completed |
NCT00842790 -
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
|
N/A | |
Completed |
NCT00529802 -
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
|
Phase 2 | |
Completed |
NCT00387764 -
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
|
Phase 3 | |
Completed |
NCT00338884 -
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
|
Phase 2 | |
Completed |
NCT00356460 -
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
|
Phase 1 | |
Completed |
NCT00095186 -
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
Completed |
NCT00079612 -
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04489771 -
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
|
Phase 2 | |
Completed |
NCT00516672 -
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT05104905 -
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT03111901 -
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 |